xMedica

NCT07000357ClinicalTrials.gov

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk…

Phase 315,100 participants sought1,452 sites36 countries

Categories

Cardiovascular100%

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered before enrolment beganFirst posted 2025-06-02; recorded start 2025-06-04
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are randomly assignedAllocation is recorded as randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Uses blinding (masking)A masking level is recorded in the record
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 1019 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 1365 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEGA

A very large study, international in scope: 15,100 participants (target), run at 1,452 sites, across 36 countries.

How this score is built
  • Enrolment39/40

    15,100 participants (target)

  • Site count25/25

    1,365 sites

  • Country count15/15

    36 countries

  • Planned duration9/10

    Planned over about 54 months

  • Sponsor scale10/10

    AstraZeneca has led 991 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.

Conditions

  • Cardiovascular Disease

Eligibility

SexAll
Ages18 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Meets one of the following: 1. Participants with history of an ASCVD event: Participants ≥ 18 years of age at the time of signing the ICF with a history of MI or ischaemic stroke suspected to be due to atherosclerotic vascular disease ≥ 1 month prior to randomisation (presumed lacunar or cardioembolic strokes are not qualifying events), or revascularisation for symptomatic lower limb PAD any time prior to screening Additional risk factors based on the level of the LDL-C and timing of MI or stroke: o Participants with an LDL-C ≥ 75 mg/dL (≥ 1.9 mmol/L) need to have at least one of the other additional risk factors (i to viii) below. ii) T2DM requiring ongoing medical therapy iii) Age ≥ 65 years v) Previous above ankle amputation due to PAD vi) Previous diagnosis of non-end stage CKD 2. Participants at increased risk of a first ASCVD event: Male participant ≥ 50 years of age or female participant ≥ 55 years of age at the time of signing the ICF with LDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L), with no prior history of MI, ischaemic stroke due to atherosclerotic disease, or leg revascularisation for symptomatic lower limb PAD, and with diagnostic evidence of at least one of the following disease categories (i, ii, or iii): (i) Significant atherosclerotic artery disease (ii) High-risk Type 1 or Type 2 diabetes mellitus with manifestation of at least one of the following end-organ diseases: 1. Nephropathy - Persistent (≥ 2 readings) microalbuminuria (urine albumin/creatinine ratio ≥ 30 mg/g) and/or persistent eGFR \< 60 mL/min/1.73 m2. At least one reading must come from the medical record within the last 12 months in addition to the reading from screening 2. Retinopathy - Treated diabetic retinopathy (surgical intervention or injectable therapy) or prior diagnosis made by a relevant healthcare specialist 3. Neuropathy - Treated neuropathy (medical therapy for pain relief or symptom alleviation) or prior diagnosis made by a relevant healthcare specialist 4. ABI \< 0.9 or \> 1.4 - confirmed either in study during screening or randomisation, or from the medical record within the last 5 years (iii) Documented atherosclerosis of less significance For (ii) and (iii), participants need to have at least one of the additional risk factors below: <!-- --> 1. CKD with eGFR x mL/min/1.73 m2 2. Current tobacco use 3. Age ≥ 65 4. T2DM (if included on the less significant atherosclerosis criterion iii) * Participants should receive a background lipid lowering regimen anticipated to achieve at least a \~50% reduction in LDL-C. Except in cases of intolerance, the regimen should include a high intensity statin therapy or lower intensity statin therapy in combination with an oral agent with proven outcome benefit (eg, ezetimibe and/or bempedoic acid). Participants must achieve a stable background lipid lowering therapy \> 28 days before screening. Exclusion criteria: * Any underlying known disease, or condition including homozygous familial hypercholesterolaemia, or LDL or plasma apheresis within 12 months prior to randomisation, that, in the opinion of the investigator, might interfere with the interpretation of the clinical study results. * Any revascularisation procedure planned within the next 3 months. * Available imaging assessment within the last 3 years showing either coronary calcium score of zero, or a coronary computed tomography angiography with no atherosclerosis. * Calculated eGFR \< 15 mL /min/1.73 m2 at screening. * Any laboratory values with the following deviations at screening: * AST or ALT \> 3 × ULN * TBL \> 2 × ULN (except for participants with Gilbert's syndrome where TBL 3 × ULN is acceptable provided direct bilirubin \< 1.5 × ULN) * Fasting triglycerides ≥ 400 mg/dL (≥ 4.52 mmol/L). * Creatine kinase \> 5 × ULN * Urine albumin/creatinine ratio ≥ 500 mg/g * Uncontrolled T2DM defined as HbA1c ≥ 9.5% at screening. * Inadequately treated hypothyroidism defined as TSH \> 1.5 × ULN at screening or participants whose thyroid replacement therapy was initiated or modified within the last 3 months prior to screening. * Use of mipomersen or lomitapide (cholesterol-lowering medications) within 12 months of screening or planned use during the study. * Use of gemfibrozil within one week prior to the Screening Visit or planned use during the study. * Use of PCSK9 inhibitors: evolocumab/alirocumab within 12 weeks of the Screening Visit or planned use during the study, or inclisiran within 18 months of the Screening Visit or planned use during the study, or any other approved PCSK9 inhibitor use within 5 half lives prior to the Screening Visit or planned use during the study.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingQUADRUPLE (4)
Enrolment15,100 participants sought

Sponsor and collaborators

  • AstraZeneca Sponsor

Arms and interventions

  • AZD0780EXPERIMENTAL

    Participants will receive oral AZD0780 once daily

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive oral placebo once daily

Interventions

  • Drug AZD0780

    Participants will receive oral AZD0780 once daily

  • Drug Placebo

    Participants will receive oral placebo once daily

Outcome measures

  1. Primary outcome

    Time to first event of any component of MACE-PLUS

    To compare the effect of treatment with AZD0780 to placebo in reducing the risk of MACE-PLUS (the composite of CV death, myocardial infarction \[MI\], ischaemic stroke, acute lower limb ischaemia, major amputation of a vascular aetiology, and urgent arterial revascularisation)

    Time frame Up to approximately 54 months

  2. Secondary outcome

    Time to first event of any component of 3P MACE

    To compare the effect of treatment with AZD0780 to placebo in reducing the risk of 3-point (3P)-MACE (the composite of CV death, MI, and ischaemic stroke)

    Time frame Up to approximately 54 months

  3. Secondary outcome

    Time to first event of any component of MACE PLUS

    To compare the effect of treatment with AZD0780 to placebo in reducing the risk of MACE-PLUS in patients with a history of ASCVD

    Time frame Up to approximately 54 months

  4. Secondary outcome

    Time to first event of MI

    To compare the effect of treatment with AZD0780 to placebo in reducing the risk of MI

    Time frame Up to approximately 54 months

  5. Secondary outcome

    Time to first event of urgent coronary revascularisation

    To compare the effect of treatment with AZD0780 to placebo in reducing the risk of urgent coronary revascularisation

    Time frame Up to approximately 54 months

  6. Secondary outcome

    Time to CV death

    To compare the effect of treatment with AZD0780 to placebo in reducing the risk of CV death

    Time frame Up to approximately 54 months

  7. Secondary outcome

    Time to first event of MALE

    To compare the effect of treatment with AZD0780 to placebo in reducing the risk of major adverse limb event (MALE) (the composite of acute lower limb ischaemia, major amputation of vascular aetiology, and urgent lower extremity revascularisation)

    Time frame Up to approximately 54 months

  8. Secondary outcome

    Time to all-cause mortality

    To compare the effect of treatment with AZD0780 to placebo in reducing the risk of all-cause mortality

    Time frame Up to approximately 54 months

Dates

Start dateJune 4, 2025 (actual)
Primary completionOctober 26, 2029 (estimated)
CompletionOctober 26, 2029 (estimated)
First postedJune 2, 2025 (actual)
Last updatedAugust 24, 2026
Results postedNot stated in the registry record
Status last verifiedAugust 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

1,106 sites are recruiting

Argentina

FacilityCityState or regionStatus
Research SiteCABARecruiting
Research SiteCABARecruiting
Research SiteCapital FederalRecruiting
Research SiteCiudad Autonoma de Bs AsRecruiting
Research SiteCiudad de Buenos AiresRecruiting
Research SiteCiudad de Buenos AiresRecruiting
Research SiteCiudad de Buenos AiresRecruiting
Research SiteCiudad de Buenos AiresRecruiting
Research SiteCiudad de Buenos AiresRecruiting
Research SiteCiudad de RosarioRecruiting
Research SiteCórdobaRecruiting
Research SiteCórdobaRecruiting
Research SiteCórdobaRecruiting
Research SiteGodoy CruzRecruiting
Research SiteLanús EsteRecruiting
Research SiteMar del PlataRecruiting
Research SiteNueva CórdobaRecruiting
Research SiteRosarioRecruiting
Research SiteRosarioRecruiting
Research SiteRosarioRecruiting
Research SiteRosarioRecruiting
Research SiteSan JuanRecruiting
Research SiteSan Miguel de TucumánRecruiting
Research SiteSan NicolásRecruiting
Research SiteSanta RosaRecruiting
Research SiteZárateRecruiting

Brazil

FacilityCityState or regionStatus
Research SiteAracajuRecruiting
Research SiteBarretosRecruiting
Research SiteBelo HorizonteRecruiting
Research SiteBelo HorizonteRecruiting
Research SiteBelo HorizonteRecruiting
Research SiteBelémRecruiting
Research SiteBlumenauRecruiting
Research SiteBrasíliaRecruiting
Research SiteBrasíliaRecruiting
Research SiteBrasíliaRecruiting
Research SiteCampina Grande do SulRecruiting
Research SiteCampinasRecruiting
Research SiteCampinasRecruiting
Research SiteCampinasRecruiting
Research SiteCampinasRecruiting
Research SiteCriciúmaRecruiting
Research SiteCuritibaWithdrawn
Research SiteCuritibaRecruiting
Research SiteCuritibaRecruiting
Research SiteGoiâniaRecruiting
Research SiteJuiz de ForaRecruiting
Research SiteMaríliaRecruiting
Research SiteNatalRecruiting
Research SitePonta GrossaRecruiting

1,402 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

  1. August 24, 2026

    Site added

    87 sites added (1452 total)

    13651452

Registry: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT07000357